JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by MEDINA, M. A.
Right arrow Articles by FOSTER, L. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by MEDINA, M. A.
Right arrow Articles by FOSTER, L. L.
Journal of Pharmacology And Experimental Therapeutics, Vol. 169, Issue 1, 132-137, 1969
Copyright © 1969 by American Society for Pharmacology and Experimental Therapeutics


INHIBITION OF TISSUE HISTAMINE FORMATION BY DECABORANE

MIGUEL A. MEDINA 1, JUANITA H. LANDEZ 1, and LLOYD L. FOSTER 1

1 Pharmacology-Biochemistry Branch, Biosciences Division, United States Air Force School of Aerospace Medicine, Brooks Air Force Base, Texas

The effect of decaborane (B10H14) upon tissue levels of histamine and histidine decarboxylase activity was studied. In rats decaborane reduced the levels of histamine in kidney, liver, stomach and urine but had no effect on heart. Brain histamine was also diminished by 50% in mice, rats, guinea pigs and rabbits. Histamine depletion was still apparent in rat brain one week after a single injection of decaborane (15 mg/kg), whereas depletion of rat stomach histamine lasted only 48 hours. It was suggested that this may be due to a difference in the turnover rate of histamine in the two tissues. Histidine decarboxylase activity (rat glandular stomach) was strongly inhibited after injection of decaborane. Other drugs tested had no effect on rat brain histamine. The data suggest that decaborane may depress histamine levels by inhibiting histidine decarboxylase and that brain histamine may exist in different metabolic pools.

Submitted on February 11, 1969
Accepted on May 26, 1969







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1969 by the American Society for Pharmacology and Experimental Therapeutics.